Brought to you by 
CVRx to raise $93mm in Series G and enters $20mm term loan
29 Aug 2016
Executive Summary
CVRx Inc. (cardiovascular devices) raised $57.7mm through its Series G financing led by Johnson & Johnson Development Corp., which was joined by other returning shareholders New Enterprise Associates and Ysios BioFund, and first-time backers Gilde Healthcare Partners, Action Potential Venture Capital , and Windham Venture Partners. In addition, $35.3mm has already been subscribed by the investors and will close upon CVRx achieving an operational milestone. The company will use the proceeds to complete its Phase III clinical trial of its Barostim neo implantable device for chronic heart failure. CVRx also entered a term loan with Oxford Finance to help repay an existing loan.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CVRx to raise $93mm in Series G and enters $20mm term loan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice